The most read glaucoma-related article on Healio.com/OSN last month was the FDA’s approval of Bausch + Lomb’s Vyzulta, a once-daily eye drop for lowering IOP.
News from the American Academy of Ophthalmology meeting in New Orleans and an Asian approval of Eye Tech Care’s glaucoma treatment rounded out the top five.
Here is the month’s most-viewed glaucoma content:
1. FDA gives nod to Bausch + Lomb’s once-daily glaucoma drops
Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) is indicated for the reduction of IOP in patients with open-angle glaucoma or
Uncategorized